TecentriqTecentriq is the drug that pela was combined with in the GOBLET trial we are learning results from this week.
I spent some time on the Roche web site and related sources to learn a bit more about it.
Here is their brief summary about recent sales:
Tecentriq (first approved in 2016; CHF 2.7 billion, +10%). Cancer immunotherapy (either alone or in combinations) for various types of cancer, e.g. lung, bladder, breast and liver cancer. Sales increased mostly due to the higher demand in the United States and Europe. Sales in Japan decreased, primarily due to governmental price cuts. Tencentriq sales amount to 10% of current global pharma sales and is one of their most impotant emerging drugs.
Here is the product monograph:
TECENTRIQ®, indicated for:
• in combination with nab-paclitaxel, for the treatment of adult patients with unresectable,
locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD- L1 expression ≥ 1%, and who have not received prior chemotherapy for metastatic disease.
has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for TECENTRIQ®, please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health- products/drug-products/notice-compliance/conditions.html
TECENTRIQ®, indicated for:
-
in combination with carboplatin and etoposide for the first-line treatment of adult patients
with extensive-stage small cell lung cancer (ES-SCLC).
-
as monotherapy for adjuvant treatment following complete resection and no progression
after platinum-based adjuvant chemotherapy for adult patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs)
-
as monotherapy for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour- infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.
-
in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic non-squamous NSCLC.
-
in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumour aberrations.
-
for the treatment of adult patients with locally advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic
NOTE THE WIDE ARRAY OF INDICATIONS FOR WHICH TENCENTRIQ IS ALREADY APPROVED.
ONCY has another trial with Tencentriq in HR neg BC in the window of opportunity study started a couple of years back. We get those results in December.
It is quite possible that pela could work well in combination with Tencentirq in several or all of these indications.
Consider what that would mean for Roche's sales, and success in achieving efficacy.
Consider what that would mean for an ONCY buyout price.